11.28.16 By Sanofi Le Hub
The Access to Medicine (ATM) Index, published every two years, is an independent ranking of 20 of the world’s leading pharmaceutical companies. Sanofi performed well in the 2016 index, rising two places to 6th overall.
The Access to Medicine Foundation works to encourage companies to act responsibly and use practices that benefit some of the most vulnerable populations worldwide. For example, by making medicines more available at a lower cost, pharmaceutical companies can help make a vast improvement to the lives of millions of people in the world’s poorest countries.
The 2016 ATM Index shows Sanofi firmly positioned in the top half of the table. Its 6th place is the result of a particularly strong performance in two categories: Research & Development, and Pricing, Manufacturing & Distribution. The company’s commitment to exploring the link between health and climate change was also cited as a key strength.
“We are pleased to have progressed in the rankings of the ATM index. However, we can still further improve the availability of our medicines and vaccines for those at highest need in vulnerable communities. The progress we have made in access management, R&D, compliance and equitable pricing has been recognized in the Index and this gives us a base to build upon in the coming years.”
Ophra Rebiere, M.D, Vice President and Head of Corporate Social Responsibility, Sanofi
Sanofi moved from 9th to 4th in the Research and Development category. According to the detailed report published by ATM, the company has a portfolio of 158 products, the largest in the index. The pipeline consists of no fewer than 28 R&D projects, including fixed-dose combinations for treating tuberculosis and a pediatric formulation for malaria. Sanofi was also praised for sharing intellectual property with partners to speed up research into tuberculosis, malaria, and neglected tropical diseases.
In Pricing, Manufacturing & Distribution, the company climbed four places to reach the top five. This improvement was driven by a substantial improvement in equitable pricing, which is now applied to significantly more products than two years ago. Diabetes, malaria, schizophrenia, and dengue fever are among the conditions the new equitable pricing policy covers.
Sanofi improved more than any of the 20 companies in the area of Compliance. The report also gave special mention to the Company’s innovative approach to exploring the impact of climate change on human health. The publication of the report coincided with the Company’s participation at COP22 in Marrakech, where it took part in two conferences on this topic.
“A couple of years ago, we identified the impact of climate change on health as a serious challenge for the future with an impact on health, especially related to vector-borne diseases such as dengue and malaria, which could expand beyond their usual areas. Climate change and health are one of the three strategic pillars of our corporate social responsibility policy, along with our contribution to public health and to the life of our communities”.
The ATM Index covers seven categories: General Access to Medicine Management; Market Influence & Compliance; Research & Development; Pricing, Manufacturing & Distribution; Patents & Licensing;
Capacity Building; and Product Donations. Sanofi has always made responding to the detailed questionnaire on which the research is based a key priority.
Launched in 2004, the index has been published every two years since 2008. It is the work of a Dutch-based not-for-profit foundation that receives financial support from several governments, in addition to funding from the Bill and Melinda Gates Foundation.
Meeting with François Bompart, Vice-President and Medical Director, Sanofi Access to Medicines department
Sanofi has responded to the ATM Index ever since it was launched in 2004. What does it represent for Sanofi – and more specifically for your department, Access to Medicines?
F.B.: Although it’s not the only performance indicator for the pharmaceutical industry, the Access to Medicine index is particularly important for Sanofi because it reflects the outside world’s expectations of our sector. In addition, the criteria used by the index are useful because they help us to make improvements – they encourage us to rethink our positioning, our operating methods, and even our priorities.
How does the Access to Medicines department contribute to the index?
F.B.: We work alongside the Sanofi team responsible for replying to the ATM Index. We provide data that corresponds to our initiatives, and we also help them to communicate Sanofi’s positioning in terms of the needs and expectations we have identified during our collaborations with international players in the healthcare sector. As our Access to Medicines team works in the field of global health, they are in very regular contact with NGOs, foundations and the scientific community. This not only allows us to understand their viewpoints better, but also to also enhance the relevance of our replies to the ATM index.
Recommended by Sanofi Le Hub
01.17.17 By Sanofi Le Hub
12.21.16 By Sanofi Le Hub
12.14.16 By Sanofi Le Hub
10.28.16 | By Sanofi Le Hub
10.24.16 | By Sanofi Le Hub
10.14.16 | By Sanofi Le Hub
10.07.16 | From WHO
09.29.16 | By Sanofi Le Hub
09.21.16 | By Sanofi Le Hub
09.15.16 | By Sanofi Le Hub
09.09.16 | By Sanofi Le Hub
09.01.16 | By Sanofi Le Hub
08.24.16 | By Sanofi.fr
08.12.16 | By Sanofi Le Hub
08.03.16 | By Sanofi Le Hub
07.26.16 | By Sanofi Le Hub
07.21.16 | By Sanofi Le Hub
07.01.16 | From BIOtechNOW
06.27.16 | By Sanofi Le Hub
06.21.16 | By Sanofi Le Hub
06.15.16 | By Sanofi Le Hub
06.10.16 | By Sanofi Le Hub